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Online only materials: This article contains online-only material. The following should 38 appear online-only: Table 1  39  40  Video: no  41  1 Key Words: endophthalmitis, anti-VEGF injection, bevacizumab, ranibizumab, AMD, 2 risk factor 3 Objective: Describe outcomes of and risk factors for endophthalmitis following 1 intravitreal anti-VEGF injection. 2 3
Design: Single-center, consecutive, case series and retrospective case-control study 4 5
Participants: Between 1/1/09 and 5/31/10, 16 vitreoretinal surgeons administered a total 6 of 27,736 injections. During this period, twenty-three cases of presumed infectious 7 endophthalmitis occurred. Each surgeon used their own preferred injection technique. 8 9
Intervention: 10 Vitreous and/or aqueous tap with intravitreal antibiotic injection and subsequent topical 11 antibiotic and steroid drops. 12 13
Main Outcome Measures: Visual acuity, bladed lid speculum use, conjunctival 14 displacement, hemisphere of injection, bevacizumab vs. ranibizumab, and infectious 15 organism. 16 17
Results: Seven of 23 cases were culture-positive; three grew coagulase negative 18
Staphylococcus. All cases presented with pain and vitritis on average 3.4 days (range 1 -19 6) after injection, with no difference between culture-positive and culture-negative 20 groups. Eighteen of 23 cases (78%) had a hypopyon. 16 of 23 cases returned to baseline 21 vision (+/-2 lines) within three months. Neither lid speculum use (0.10% vs. 0.066% in 22 the no use group, p = 0.27), conjunctival displacement (0.11% vs. 0.076% no 23 displacement, p = 0.43), hemisphere of injection (0.11% superior vs. 0.079% inferior, p = 24 0.56), or bevacizumab vs. ranibizumab (0.11% vs 0.066%, p = 0.21) affected risk. 25 Analysis of only culture positive results yielded similar results. There was no statistically 26 significant difference between the proportion of culture-negative cases after bevacizumab 27 (83%) versus ranibizumab injection (55%, p = 0.13). 28 29
Conclusion: Most patients who develop presumed infectious endophthalmitis after anti-30 VEGF injection regained baseline vision after treatment. Bladed lid speculum use, 31 conjunctival displacement, hemisphere of injection, and type of anti-VEGF agent did not 32 affect risk. We did not detect a difference in culture-negative endophthalmitis rates after 33 bevacizumab versus ranibizumab injection . Neither the presence of pain, vitritis,  34 decreased vision, or hypopyon, nor the interval between injection and development of 35 symptoms, differentiated culture-positive from culture-negative cases. As a subgroup of 36 patients have poor outcomes, a low threshold for vitreous tap with intravitreal antibiotic 37 injection may be warranted. 38 39 40
Introduction: 1
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have 2 revolutionized the treatment of neovascular age-related macular degeneration (AMD). 3
The use of these medications continues to increase as their indications expand, including 4 for diseases such as retinal vein occlusions 1, 2 , neovascular glaucoma 3 , and diabetic 5 macular edema 4 . 6
Infectious endophthalmitis remains one of the most feared complications of 7 intravitreal injections. Endophthalmitis can lead to apoptosis of ganglion cells, bipolar 8 cells, and photoreceptors 5 , or to retinal detachment, which can all lead to significant 9 vision loss or to loss of the eye. 10 Few clinical studies describe visual outcomes after post-injection 11 endophthalmitis [6] [7] [8] and prednisolone acetate 1% drops every hour, as well as atropine sulfate 1% drops twice 20 a day. Patients were followed daily until they had evidence of clinical improvement, at 21 which time the drops were slowly tapered and examination intervals were gradually 22
extended. Antibiotic drops also were modified based on culture sensitivity data. 23 24
Inclusion and exclusion criteria: 25
All eyes with presumed infectious endophthalmitis warranting tap and inject were 26 included in this case series. The criteria for tap and inject were dependent on the 27 judgment of individual vitreoretinal specialists, but universally included decreased visual 28 acuity, the presence of pain, and the presence of vitritis within one week of intravitreal 29
anti-VEGF injection. Patients not included in this case series were those with mild post-30 injection anterior chamber inflammation (1+ or less), who improved on topical 31 corticosteroid and antibiotic drops without undergoing tap and inject. 32 33
Endophthalmitis surveillance log: 34 One researcher (CPS) recorded data for all patients undergoing tap and inject in 35 an infection surveillance log. These data included the presence of pain, vitritis, and/or 36 hypopyon, visual acuity before the causative injection and at time of tap and inject 37 (Snellen acuity, not best corrected), date of causative anti-VEGF injection, date of tap 38 and inject, office location, injecting vitreoretinal surgeon, type of anti-VEGF injection 39
(bevacizumab versus ranibizumab), lot number, underlying retinal diagnosis, number of 40 prior anti-VEGF injections, lens status, source of tap (vitreous or aqueous), identified 41 organism, and antibiotic specificities. At the end of the surveillance period, charts were 42 retrospectively reviewed to collect follow-up data. 43 44
Analysis of case series and case-control study: 45 revised 12/2/11 Clinical variables of presumed infectious endophthalmitis were analyzed using 1 Excel (Microsoft, Redmond, WA). These features included the presence of pain,  2 hypopyon, vitritis, decreased vision, and duration between causative anti-VEGF injection 3 and tap and inject. Outcome data included return of baseline visual acuity (plus or minus 4 two lines of Snellen acuity, not best-corrected) and need for pars plana vitrectomy. 5
To evaluate risk factors for developing endophthalmitis, the authors conducted a 6 retrospective case-control analysis. The total number of bevacizumab and ranibizumab 7 injections administered was determined using billing data. The number of anti-VEGF 8 injections was also stratified by office location and injecting vitreoretinal surgeon. 9
Several risk factors for presumed infectious endophthalmitis after anti-VEGF injection 10 were examined. These included bladed lid speculum use, conjunctival displacement with 11 a sterile cotton tip applicator prior to injection, superior versus inferior hemisphere of 12 injection, the use of bevicizumab versus ranibizumab, office location, injecting 13
vitreoretinal specialist, and lot number of the specific anti-VEGF agent. A two-sample 14 test of proportion was performed using Stata 9 (College Park, TX). Analysis was done 15 for all cases of presumed infectious endophthamitis and further stratified for culture-16 positive and culture-negative cases. 17 18
Results 19 20
Clinical Features 21
During the 17-month study period, a total of 27,736 consecutive intravitreal anti-22
VEGF injections were administered, including 10,958 bevacizumab and 16,778 23 ranibizumab injections. Twenty-three of these cases underwent emergent tap and inject 24 for presumed infectious endophthalmitis (0.083%, 95% confidence interval 0.049% to 25 0.12%). Twenty-one of these eyes received anti-VEGF injection for neovascular AMD, 26
while two were treated for macular edema secondary to branch retinal vein occlusion. 27
All cases of presumed infectious endophthalmitis presented with pain, vitritis, and 28 decreased visual acuity. Most cases had a hypopyon at time of tap and inject (18 of 23 29 eyes, 78%). Five of seven culture-positive cases presented with hypopyon (71%, 30 p=XXX). 31 There was an average of 3.4 days (range 1 to 6 days) between administration of 32 anti-VEGF injection and emergent tap and inject. This average was similar between 33 culture-negative (3.5 days, range 1 to 6 days) and culture-positive cases (3.1 days, range 34 1 to 5 days, p = 0.54). One culture-negative case presenting 17 days after injection was 35 excluded from this analysis because the patient's nursing home delayed seeking medical 36 attention. 37
Vitreous tap was performed in all cases, and an adequate specimen was obtained 38 in 14 of 23 cases. When the vitreous tap was unsuccessful, an aqueous tap was performed 39 successfully in the remaining 9 of 23 cases. An infectious organism was identified from 40 vitreous and/or aqueous biopsy in 30.4% of patients Most cases (16 of 23, 70%) returned to baseline vision (+/-2 lines) within three 1 months (see Table 1 , available at http://aaojournal.org). Four more cases returned to 2 baseline vision at six months; a total of 83% of cases had recovery of baseline vision. 3
Specifically, the three eyes that did not return to baseline were as follows: the vision of 4 one patient dropped from 20/300 to no light perception after retinal detachment with 5 subsequent retinal detachment repair, one from 20/40 to counting fingers after retinal 6 detachment repair, one from 20/400 to counting fingers, and one from 20/50 to 20/100. 7
Four of 23 cases (17%) underwent pars plana vitrectomy three days to 3 weeks after 8 initial tap and inject for retinal detachment, vitreous hemorrhage, or worsening 9 endophthalmitis. 10 Of the seven culture-positive cases, four returned to baseline vision by three 11 months and an additional case returned by six months (71%). Of the two culture-positive 12
eyes not returning to baseline vision, both underwent subsequent pars plana vitrectomy 13 for retinal detachment. These eyes grew Streptococcus viridans and Streptococcus mitus, 14
respectively. 15
Of the 16 culture-negative cases, 13 returned to baseline vision by three months 16 with another two returning by six months (94%). There was no significant difference in 17 the visual recovery rate between culture positive and culture-negative cases (p = 0.14).Of 18 note, one patient developed pain, decreased vision, and hypopyon twice after sequential 19 bevacizumab injection (patient's third and fourth injections). During the first episode, the 20 patient underwent tap and inject three days after causative bevacizumab injection and 21
improved to baseline visual acuity at six weeks. During the second episode, the patient 22
was treated initially with hourly prednisolone acetate drops and had continued worsening 23 of inflammation. The patient underwent tap and inject three days after causative 24 bevacizumab injection, and did not regain baseline visual acuity at six months. This eye 25 was counted twice, once for each episode. 26 27
Risk Factors 28
Cases of endophthalmitis occurred in nine of 16 offices by nine of 16 injecting 29 vitreoretinal surgeons. There were no clusters of endophthalmitis with any individual 30 treating physician or in any particular office location. There were no trends associated 31
with lot numbers of bevacizumab or ranibizumab injections. 32
No modifiable risk factors were identified (see Table 2 ). Neither lid speculum use 33
[0.10% (13 of 12,500) vs. 0.066% (10 of 15,236) in the no use group, p = 0.27, 95% 34 confidence interval of the difference -0.031 to 0.11%], conjunctival displacement [0.11% 35 (6 of 5,421) vs. 0.076% (17 of 22,315) no displacement, p = 0.43, 95% confidence 36 interval of the difference -0.061 to 0.13%],], hemisphere of injection [0.11% (4 of 3,683) 37 superior vs. 0.079% (19 of 24,053) inferior, p = 0.56, 95% confidence interval of the 38 difference -0.082 to 0.14%],], or bevacizumab (0.11%, 12 of 10,958) vs. ranibizumab 39 (0.066%, 11 of 16,778, p = 0.21, 95% confidence interval of the difference -0.030 to 40 0.12%],) affected risk. Results were similar with analysis of only culture-positive cases 41
[0.032% (4 of 12,500) vs. 0.020% (3 of 15,236) in the no speculum group (p = 0.52), 42 0.018% (1 of 5,421) vs. 0.027% (6 of 22,315) in the no conjunctival displacement group 43 (p = 0.73), 0.054% (2 of 3,683) superior vs. 0.021% (5 of 24,053) inferior hemisphere of 44 injection (p = 0.23), and 0.018% (2 of 10,958) post-bevacizumab vs. 0.030% (5 of 45 16,778) post-ranibizumab (p = 0.55)]. The proportion of culture-negative cases was 46 similar after bevacizumab (83%, 10 of 12) and ranibizumab injection (55%, 6 of 11, p = 1 0.13). 2
Power calculations revealed that 101,958 injections evenly split between two 3 groups would be needed to detect a difference between 0.05% and 0.10% with an alpha 4 of 0.05 and a beta of 0.20. 5 6
Discussion 7
This large, single-center cases series and case-control study evaluated cases with 8 presumed infectious endophthalmitis occurring after intravitreal anti-VEGF injection. 9
Overall, we detected 23 cases of endophthalmitis after 27,736 injections for an incidence 10 of 0.083%. All cases presented with pain, decreased visual acuity, and vitritis three to 11 four days after intravitreal anti-VEGF injection; most eyes had hypopyon. These features 12 did not help distinguish between culture-positive and culture-negative cases. Most cases 13 returned to baseline visual acuity within three to six months, though some suffered 14 significant visual loss. There were no modifiable risk factors for post-injection 15 endophthalmitis, including the use of a bladed lid speculum, conjunctival displacement 16 with a sterile cotton tip applicator, superior versus inferior hemisphere of injection, and 17 the use of bevacizumab versus ranibizumab. 18
The reported rates of endophthalmitis after intravitreal anti-VEGF injection vary 19 between institutions, study designs, and definitions of endophthalmitis. Our rate is 20 consistent with other large prospective trials. The Minimally Classic/Occult Trial of the 21
Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) 22 study reported an endophthalmitis incidence of 0.05% (5 cases per 10,443 injections) 11 , 23
identical to the rate reported in the Anti-VEGF Antibody for the Treatment of 24
Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) study 12, 13 (3 25 cases per 5,921 injections). However, 14 patients in the MARINA trial and 10 patients in 26
the ANCHOR trial experienced 2+ to 4+ inflammation on slit-lamp examination and 27
were not treated for presumed endophthalmitis. In contrast, at our institution, nearly all 28 patients who develop vitritis, or who develop significant anterior chamber cellular 29 reaction, would be given intravitreal antibiotics. Including these untreated patients, the 30 clinically presumed endophthalmitis rate increases to 0.18% in the MARINA trial and 31 0.22% in the ANCHOR trial. It is possible that our study includes eyes with post-32 injection inflammation that would have been observed in the MARINA and ANCHOR 33 trials. 34
Endophthalmitis rates in retrospective studies vary tremendously. Fintak and 35 colleagues 14 identified cases of endophthalmitis from billing records at four institutions, 36
reporting a rate of 0.02% (6 of 26,905 injections). All injecting physicians used a lid 37 speculum and 5% to 10% topical povidone-iodine drops to disinfect the ocular surface; 38 some physicians used 10% povidone-iodine soaked swabs to clean the eyelid skin, 39 eyelashes, and lid margin. Pilli and colleagues 8 also reported a similarly low rate of post-40 injection endophthalmitis in an office setting (0.029%, 3 of 10,254 injections). In this 41 study, the authors retrospectively collected endophthalmitis cases by reviewing case 42 notes and from conversations with referral sources and other vitreoretinal groups in the 43 area. Patients were prepped with 5% povidone-iodine drops. A lid speculum was used 44 based on the surgeon's discretion. In both of these studies, the retrospective study design 45 could have missed endophthalmitis cases, underestimating the incidence of this rare 46 complication. At the other end of the spectrum, Fong and colleagues 15 reported a 10-fold 1 higher rate of endophthalmitis in a retrospective study of intravitreal bevacizumab and 2 ranbizumab injections (0.26%, 4 of 1,553 total injections), collecting cases from an AMD 3 registry amassed from injection logs. Details were not given regarding the injection 4 technique. 5
Non-infectious endophthalmitis, or uveitis, has been reported after intravitreal 6 anti-VEGF injection, particularly after bevacizumab injection 9, 10, 16, 17 . In our study, 7 however, the proportion of culture-negative-and possibly non-infectious-8 endophthalmitis cases was similar after bevacizumab and ranibizumab injections. 9
Prior studies have offered clinical criteria to distinguish between culture-positive 10 and culture-negative endophthalmitis. Ness and colleagues 9 reported 10 cases of uveitis, 11
termed toxic vitritis, after bevacizumab injection. They felt the timing and severity of 12 pain helped distinguish it from infectious endophthalmitis. All toxic vitritis cases 13
presented within 48 hours with mild to no pain. A hypopyon was not a distinguishing 14 feature; six cases of toxic vitritis presented with hypopyon. The authors attributed these 15 cases to a toxic reaction from the brand of syringe used for injection. Georgopoulos and 16 colleagues 10 reported eight cases of non-infectious endophthalmitis after bevacizumab. 17
All cases presented within two days of injection without hypopyon. Only one patient had 18 pain. Mezad-Koursh and colleagues found that later presentation, pain, keratic 19
precipitates, fibrin, hypopyon, and anterior synechiae were more typical of culture 20 positive endophthalmitis 18 . 21
In contrast, our study suggests that one cannot clinically distinguish between 22
culture-positive and culture-negative endophthalmitis after anti-VEGF injection. All 23 cases in our series had pain, decreased vision, and vitritis. Both culture-positive and 24 culture-negative cases presented an average of three to four days after injection. Most 25 patients in both groups had a hypopyon. Anecdotally, one case of endophthalmitis due to 26
Streptococcus viridans with a final visual acuity of no light perception initially presented 27 two days after injection with 3+ cell and no hypopyon. Another patient presented with 28 sequential hypopyon endophthalmitis after bevacizumab. The first episode resolved to 29 baseline visual acuity six weeks after tap and inject. The second episode did not improve 30 with hourly topical prednisolone acetate, and required tap and inject to control the 31 inflammation; the vision never returned to baseline visual acuity at six months. We 32
suggest that presumed infectious endophthalmitis should be considered in all instances 33 with post-injection inflammation in the vitreous cavity greater than 1+ cell, and strong 34 consideration should be given to treating these cases with emergent tap and injection of 35 intravitreal antibiotics. 36
Although most cases with endophthalmitis after intravitreal anti-VEGF injection 37 returned to baseline visual acuity within three to six months, 17% lost more than two 38 lines at final follow-up. These outcomes are similar to those reported by Klein and 39 colleagues 6 , and worse than those in other smaller studies 8, 19 . There was no significant 40 difference in rates of visual recovery between culture-positive and culture-negative cases. 41
Only a small percentage of cases (17%) required pars plana vitrectomy. 42
Several authors have emphasized the role of specific aspects of prepping 43 technique to prevent endophthalmitis after intravitreal injection. The only proven 44 endophthalmitis prophylaxis remains topical povidone-iodine to sterilize the ocular 45 surface 20, 21 . It is important to sterilize the ocular surface with povidone-iodine before 46 applying a viscous anesthetic; viscous gel can form a barrier preventing povidone-iodine 1 from coming in contact with conjunctival bacteria 22, 23 . Further, physicians and patients 2 should avoid talking, coughing, and sneezing during anti-VEGF injection administration 3 to prevent contamination with oral flora 24, 25 . Streptococcus species isolates, bacteria 4 commonly found in oral flora and isolated in two of our cases, occur three to four times 5 more frequent in endophthalmitis after intravitreal injection than after intraocular 6 surgery 24, 25 . 7
The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial 26 8 investigators felt the risk of post-injection endophthalmitis could be modified by 9
vigilance to an aseptic injection technique. Their initial endophthalmitis rate was 0.18% 10 per injection (13 cases in 7,171 injections). After amending the injection protocol to 11 include a sterile drape and an additional pre-injection antibiotic or povidone-iodine flush, 12 rates decreased to 0.04% (2 of 4,465) at centers adopting the amended protocol. They 13 attributed 75% of cases (9 of 12) to the failure of using a lid speculum. applicator when injecting through the pars plana in an effort to avoid a straight tract for 45 bacteria to enter through the conjunctiva and sclera into the vitreous cavity 36 . Others 46 argue it is best to minimize manipulation of the ocular surface to decrease risk of 1 potential contamination. In our study, there was no difference in endophthalmitis risk 2 between those who do and do not displace conjunctiva while injecting. 3
There was no difference in endophthalmitis risk after bevacizumab or 4 ranibizumab injection in our study, similar to the findings of other studies 6, 8 . Given the 5 wide confidence intervals, however, we cannot draw strong conclusions from this result. 6
Our study has several limitations. Although we identified and recorded 7 endophthalmitis cases prospectively with an infection surveillance program, a method we 8 feel is more accurate than retrospective identification, it is possible that we 9 underestimated risk of endophthalmitis. We retrospectively reviewed charts at the end of 10 the surveillance period, which could have introduced certain biases and inaccuracies. For 11 example, our study utilized Snellen acuity, which is not as accurate as best-corrected 12 visual acuity. Also, we were unable to assess other relevant risk factors, such as degree of 13 blepharitis, because this was not systematically documented in the charts. Our culture-14 positivity rate of 30.4% was lower compared to other studies. For example, the 15
Endophthalmitis Vitrectomy Study (EVS) 37 reported that 66% of cases (138 of 202) 16
undergoing tap and inject for endophthalmitis after cataract surgery were confirmed 17 culture-positive. Their higher rate of culture-positivity may be related to their 18 methodology; they collected vitreous samples by either single port vitrectomy or needle 19 aspiration whereas we only used needle apiration. In our study, nine of 23 cases had an 20 unsuccessful vitreous biopsy and thus had aqueous biopsy alone, and in the EVS, 21
aqueous biopsy was associated with a lower confirmed laboratory infection rate (26.9%) 22
compared to undiluted vitreous (58.9%) 38 . 23
Another possible reason our culture-positivity rate was low could be that we 24
included cases of presumed non-infectious endophthalmitis. Intraocular inflammation is 25 a known possible sequeale of intravitreal anti-VEGF injection 10, 39 . Our standard practice 26 is to administer intravitreal antibiotics whenever the examing physician feels that the case 27 is more likely then non-infectious endophthalmitis. 28
Because of the low incidence of endophthalmitis, our risk factor analysis is 29 underpowered to find small differences. It is possible that our risk factor results are 30 subject to misclassification bias if the injecting vitreoretinal specialists deviated from 31 their preferred injection technique during some injections. Further, there may have been 32
undocumented variations in prepping technique in cases developing endophthalmitis. 33
In summary, the risk of endophthalmitis after intravitreal anti-VEGF injection is 34 low. The accuracy of reported rates in the literature, in part, depends on individual study 35 designs and the study's definition of "endophthalmitis". Visual outcomes are good for 36 most cases, with 83% to baseline visual acuity within three to six months. However, a 37 subgroup of infected eyes will have devastating visual outcomes. The presence or 38 absence of pain, vitritis, decreased vision, or hypopyon, and the interval between 39 injection and presentation, does not help distinguish culture-positive from culture-40 negative cases. Thus, we recommend vitreoretinal specialists have a low threshold to 41 perform emergent tap and injection of intravitreal antibiotics. This study did not identify 42 any modifiable risk factors to prevent endophthalmitis. The incidence endophthalmitis 43
does not appear to be affected by use of a lid speculum, conjunctival displacement, 44 hemisphere of injection, or use bevacizumab or ranbizumab. 45 46 18.
